Application of Preoperative NLR-based Prognostic Model in Predicting Prognosis of Intrahepatic Cholangiocarcinoma Following Radical Surgery

Overview

Journal Front Nutr

Specialty Nutritional Sciences

Date 2024 Nov 14

PMID 39539368

Authors

Shuo Qi

Zhongzhi Ma

Lian Shen

Jun Wang

Lei Zhou

Bingzhang Tian

Changjun Liu

Kang Chen

Wei Cheng

Affiliations

Soon will be listed here.

Abstract

Purpose: To investigate the application value of the neutrophil to lymphocyte count ratio (NLR) in the prognostic analysis of intrahepatic cholangiocarcinoma (ICC) after radical resection, and to offer guidance for the individualized perioperative diagnosis and treatment of ICC.

Methods: The clinical data of 360 patients diagnosed with ICC following radical surgery were retrospectively analyzed. The cut-off value of NLR was calculated using the minimum -value method, and then divided into High-NLR (H-NLR) group and Low-NLR (L-NLR) group according to the NLR cut-off value. The prognostic value of NLR in ICC was analyzed. Subsequently, the patients were divided into the hepatolithiasis-related intrahepatic cholangiocarcinoma (HICC) group and the non-hepatolithiasis-related intrahepatic cholangiocarcinoma (NHICC) group based on whether they combined with hepatolithiasis. Multiple regression models were constructed based on NLR and clinicopathological indicators to verify the application value of prognostic models in the survival and recurrence of ICC patients after radical surgery.

Results: The cut-off value of NLR was 2.36, and the survival analysis disclosed that overall ICC patients with NLR ≥ 2.36 manifested a poor 5-year survival rate and a higher tumor recurrence rate ( < 0.001). In the HICC group, patients with H-NLR presented a poor 5-year survival rate and a higher tumor recurrence rate compared with L-NLR ( < 0.001). The NLR-based survival/recurrence prediction models in the HICC group demonstrated excellent predictive capacity (H-L test: 0.359/0.680, AUC: 0.764/0.791). In the NHICC group, patients with H-NLR exhibited a poor 5-year survival rate compared with L-NLR ( < 0.001), yet there was no significant difference in tumor recurrence between the two groups ( = 0.071). The NLR-based survival prediction model in the NHICC group demonstrated acceptable predictive ability (H-L test: 0.268, AUC: 0.729), while the NLR-based recurrence prediction model did not show an effective predictive ability (H-L test: 0.01, AUC: 0.649).

Conclusion: NLR is an independent risk factor influencing postoperative survival and recurrence in ICC patients, particularly in HICC patients. Preoperative NLR ≥ 2.36 suggests that patients might have a poor prognosis. The survival and recurrence prediction model constructed based on NLR and other clinical indicators demonstrates good prediction accuracy and can effectively predict the risk of postoperative adverse prognosis in patients with HICC. This study offers a novel idea for the clinical treatment of HICC patients.

References

Yoh T, Hatano E, Kasai Y, Fuji H, Nishi K, Toriguchi K . Serum Nardilysin, a Surrogate Marker for Epithelial-Mesenchymal Transition, Predicts Prognosis of Intrahepatic Cholangiocarcinoma after Surgical Resection. Clin Cancer Res. 2018; 25(2):619-628. DOI: 10.1158/1078-0432.CCR-18-0124. View

Moris D, Palta M, Kim C, Allen P, Morse M, Lidsky M . Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians. CA Cancer J Clin. 2022; 73(2):198-222. DOI: 10.3322/caac.21759. View

Tsilimigras D, Hyer J, Paredes A, Diaz A, Moris D, Guglielmi A . A Novel Classification of Intrahepatic Cholangiocarcinoma Phenotypes Using Machine Learning Techniques: An International Multi-Institutional Analysis. Ann Surg Oncol. 2020; 27(13):5224-5232. DOI: 10.1245/s10434-020-08696-z. View

ORourke C, Salati M, Rae C, Carpino G, Leslie H, Pea A . Molecular portraits of patients with intrahepatic cholangiocarcinoma who diverge as rapid progressors or long survivors on chemotherapy. Gut. 2023; 73(3):496-508. PMC: 10894814. DOI: 10.1136/gutjnl-2023-330748. View

Ramouz A, Ali-Hasan-Al-Saegh S, Shafiei S, Fakour S, Khajeh E, Majlesara A . Repeat liver resection for recurrent intrahepatic cholangiocarcinoma: meta-analysis. Br J Surg. 2022; 109(7):580-587. DOI: 10.1093/bjs/znac075. View

Gavriilidis P, Pawlik T . Inflammatory indicators such as systemic immune inflammation index (SIII), systemic inflammatory response index (SIRI), neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic factors of curative hepatic resections.... Hepatobiliary Surg Nutr. 2024; 13(3):509-511. PMC: 11190525. DOI: 10.21037/hbsn-23-631. View

Wei T, Zhang X, He J, Popescu I, Marques H, Aldrighetti L . Prognostic impact of perineural invasion in intrahepatic cholangiocarcinoma: multicentre study. Br J Surg. 2022; 109(7):610-616. DOI: 10.1093/bjs/znac098. View

Spencer K, Pappas L, Baiev I, Maurer J, Bocobo A, Zhang K . Molecular profiling and treatment pattern differences between intrahepatic and extrahepatic cholangiocarcinoma. J Natl Cancer Inst. 2023; 115(7):870-880. PMC: 10323903. DOI: 10.1093/jnci/djad046. View

An L, Zheng R, Zhang S, Chen R, Wang S, Sun K . Hepatocellular carcinoma and intrahepatic cholangiocarcinoma incidence between 2006 and 2015 in China: estimates based on data from 188 population-based cancer registries. Hepatobiliary Surg Nutr. 2023; 12(1):45-55. PMC: 9944524. DOI: 10.21037/hbsn-21-75. View

10.

Neumann C, Schneider F, Hilfenhaus G, Vecchione L, Felsenstein M, Ihlow J . Inflammation-Based Prognostic Scores in Pancreatic Cancer Patients-A Single-Center Analysis of 1294 Patients within the Last Decade. Cancers (Basel). 2023; 15(8). PMC: 10136644. DOI: 10.3390/cancers15082367. View

11.

La Vecchia C, Lotti M, Colombo M . Asbestos Exposure and Increased Risk of Intrahepatic Cholangiocarcinoma: Enough to Infer Causality?. Gastroenterology. 2020; 159(2):794-795. DOI: 10.1053/j.gastro.2020.06.037. View

12.

Moazzam Z, Alaimo L, Endo Y, Lima H, Ruzzenente A, Guglielmi A . Combined Tumor Burden Score and Carbohydrate Antigen 19-9 Grading System to Predict Outcomes Among Patients with Intrahepatic Cholangiocarcinoma. J Am Coll Surg. 2023; 236(4):804-813. DOI: 10.1097/XCS.0000000000000557. View

13.

Zhou S, Xin H, Sun R, Zhou Z, Hu Z, Luo C . Association of KRAS Variant Subtypes With Survival and Recurrence in Patients With Surgically Treated Intrahepatic Cholangiocarcinoma. JAMA Surg. 2021; 157(1):59-65. PMC: 8567187. DOI: 10.1001/jamasurg.2021.5679. View

14.

Sapisochin G, Ivanics T, Heimbach J . Liver Transplantation for Intrahepatic Cholangiocarcinoma: Ready for Prime Time?. Hepatology. 2021; 75(2):455-472. DOI: 10.1002/hep.32258. View

15.

Ivy M, Baison G, Griffin C, Welch A, White P, Farivar A . Thirty- and 90-Day Morbidity and Mortality by Clavien-Dindo after Surgery for Antireflux and Hiatal Hernia. J Am Coll Surg. 2024; 239(4):323-332. DOI: 10.1097/XCS.0000000000001114. View

16.

Tsilimigras D, Moris D, Mehta R, Paredes A, Sahara K, Guglielmi A . The systemic immune-inflammation index predicts prognosis in intrahepatic cholangiocarcinoma: an international multi-institutional analysis. HPB (Oxford). 2020; 22(12):1667-1674. DOI: 10.1016/j.hpb.2020.03.011. View

17.

Cho S, Hwang H, Kim Y, Yoo B, Han N, Kong S . Refining Classification of Cholangiocarcinoma Subtypes via Proteogenomic Integration Reveals New Therapeutic Prospects. Gastroenterology. 2023; 164(7):1293-1309. DOI: 10.1053/j.gastro.2023.02.045. View

18.

Edeline J, Touchefeu Y, Guiu B, Farge O, Tougeron D, Baumgaertner I . Radioembolization Plus Chemotherapy for First-line Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial. JAMA Oncol. 2019; 6(1):51-59. PMC: 6824230. DOI: 10.1001/jamaoncol.2019.3702. View

19.

Bo Z, Chen B, Yang Y, Yao F, Mao Y, Yao J . Machine learning radiomics to predict the early recurrence of intrahepatic cholangiocarcinoma after curative resection: A multicentre cohort study. Eur J Nucl Med Mol Imaging. 2023; 50(8):2501-2513. DOI: 10.1007/s00259-023-06184-6. View

20.

Shen H, Zhang S, Xia Y, Chen C, Huo L, Gan L . A Nomogram in Predicting Risks of Intrahepatic Cholangiocarcinoma After Partial Hepatectomy for Hepatolithiasis. J Gastrointest Surg. 2021; 25(9):2258-2267. DOI: 10.1007/s11605-021-04947-w. View